News

With NIH grant, Springbok Analytics takes on rotator cuff injuries

Springbok Analytics, a Charlottesville medical data company that creates 3D models from X-rays and MRIs, has received a $1.7 million government grant to develop a commercially viable algorithm that can detect and diagnose shoulder injuriesThe grant, announced Tuesday, comes from the National Science Foundation’s Small Business Innovation Research grant program. It follows a $51,409 grant the company received from the NIH in 2022 to start its R&D on the project.

Springbok will work with research partners at the University of Virginia, University of Wisconsin and the San Antonio Orthopedic Group on AI technology to provide “a more accurate and objective scoring system” for evaluating rotator cuff muscles and to gauge the prospects of patient surgeries.

Lara Riem, Springbok’s director of AI and data science, said in a statement the company created an “extensive digital database” of healthy and injured rotator cuffs through phase I of the project. She said that database helped it establish key metrics evaluating muscles that can be “derived precisely and automatically, at scale” from magnetic resonance images.

Springbok said completion of a phase II trial of the new analysis system will allow it to apply for commercial clearance from the Food and Drug Administration.

“Our ultimate goal at Springbok Analytics is to become the standard for how we understand human musculature and improve clinical diagnosis, injury management and human performance through innovative, AI-based technologies,” co-founder and Chief Science Officer Silvia Blemker said in a statement.

Springbok’s 3D MRI imaging services are used by teams across the NFL, NBA, MLB, NHL, Premier League and NCAA. Last April, it closed an oversubscribed $3 million seed round led by Transition Equity Partners that included participation from the NHL’s Chicago Blackhawks.

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and